Tempest Therapeutics, Inc.
Recent Filings
All 973 filings →| Form | Description | Date |
|---|---|---|
| SCHEDULE 13D/A | — | Mar 25, 2026 |
| 4 | — | Mar 25, 2026 |
| 8-K | 8-K | Mar 23, 2026 |
| 8-K | 8-K | Feb 25, 2026 |
| 8-K | 8-K | Feb 11, 2026 |
| SCHEDULE 13D | — | Feb 10, 2026 |
| 4 | — | Feb 6, 2026 |
| 3 | — | Feb 6, 2026 |
| 8-K | 8-K | Feb 6, 2026 |
| 4 | — | Jan 28, 2026 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | — | Sale | 400,000 @ $1.35 | 597,940 | Aug 12, 2024 |
| Brady Stephen R | President and CEO | Purchase | 35,000 @ $2.11 | 46,376 | Jul 3, 2024 |
| Whiting Samuel | Chief Medical Officer | Purchase | 4,672 @ $2.13 | 9,573 | Jul 2, 2024 |
| Trojanowski Justin | Corporate Controller | Purchase | 7,500 @ $2.16 | 22,168 | Jun 28, 2024 |
| Woiwode Thomas | — | Purchase | 2,118,644 @ $2.36 | 2,118,644 | Apr 29, 2022 |
| Dubensky Thomas W. | President | Purchase | 2,000 @ $4.78 | 113,343 | Jan 7, 2022 |
| Whiting Samuel | Chief Medical Officer | Purchase | 1,700 @ $4.80 | 1,901 | Jan 6, 2022 |
| Whiting Samuel | Chief Medical Officer | Award / Grant | 201 | 201 | Jun 25, 2021 |
| Xu Stella | — | Award / Grant | 579,710 | 579,710 | Jun 25, 2021 |
| Dubensky Thomas W. | President | Award / Grant | 111,343 | 111,343 | Jun 25, 2021 |